NASDAQ:CDMO - Avid Bioservices Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.33
  • Forecasted Upside: -12.01 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$19.70
▲ +0.46 (2.39%)
1 month | 3 months | 12 months
Get New Avid Bioservices Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDMO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.33
▼ -12.01% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Avid Bioservices in the last 3 months. The average price target is $17.33, with a high forecast of $22.00 and a low forecast of $9.00. The average price target represents a -12.01% upside from the last price of $19.70.
Buy
The current consensus among 3 investment analysts is to buy stock in Avid Bioservices. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2021Royal Bank of CanadaInitiated CoverageOutperform$21.00Low
i
3/16/2021Royal Bank of CanadaInitiated CoverageOutperform$21.00Medium
i
2/1/2021KeyCorpBoost Price Target$12.00 ➝ $22.00Low
i
11/9/2020KeyCorpInitiated CoverageOverweight$12.00Low
i
7/1/2020HC WainwrightReiterated RatingBuy$9.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
3/11/2020HC WainwrightReiterated RatingBuy$11.00 ➝ $9.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/10/2019HC WainwrightReiterated RatingBuy$11.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/10/2019First AnalysisUpgradeOutperform ➝ Strong-Buy$7.50High
i
12/10/2019StephensBoost Price TargetOverweight$8.00 ➝ $10.00High
i
10/16/2019StephensInitiated CoverageOverweight$8.00High
i
10/16/2019Craig HallumInitiated CoverageBuy$11.00High
i
9/6/2019HC WainwrightSet Price TargetBuy$11.00High
i
Rating by Joseph Pantginis at HC Wainwright
7/8/2019HC WainwrightReiterated RatingBuy$11.00Low
i
Rating by Joseph Pantginis at HC Wainwright
6/28/2019HC WainwrightSet Price TargetBuy$11.00High
i
Rating by Joseph Pantginis at HC Wainwright
6/28/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy$10.00High
i
5/9/2019Janney Montgomery ScottDowngradeBuy ➝ Neutral$10.00 ➝ $5.00High
i
12/11/2018HC WainwrightReiterated RatingBuy$11.00High
i
Rating by Joseph Pantginis at HC Wainwright
9/11/2018HC WainwrightBoost Price TargetBuy ➝ Buy$6.00 ➝ $11.00High
i
Rating by Joseph Pantginis at HC Wainwright
7/17/2018HC WainwrightReiterated RatingBuy$6.00High
i
Rating by J. Pantginis at HC Wainwright
6/25/2018Janney Montgomery ScottInitiated CoverageBuy$10.00High
i
5/24/2018HC WainwrightInitiated CoverageBuy$5.00High
i
Rating by J. Pantginis at HC Wainwright
3/15/2018Wells Fargo & CompanyInitiated CoverageOutperformHigh
i
3/13/2018First AnalysisInitiated CoverageOverweight$4.00Medium
i
1/5/2018Noble FinancialReiterated RatingBuyLow
i
Rating by Caroline Palomeque at Noble Financial
12/12/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Caroline Palomeque at Noble Financial
9/29/2017Noble FinancialInitiated CoverageBuy ➝ Buy$10.00Low
i
Rating by Kumaraguru Raja at Noble Financial
7/31/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Kumaraguru Raja at Noble Financial
4/6/2017Noble FinancialReiterated RatingBuyMedium
i
Rating by Mark Jordan at Noble Financial
9/13/2016Roth CapitalReiterated RatingNeutral$3.50N/A
i
Rating by Joseph Pantginis at Roth Capital
9/12/2016(FBRC)Reiterated RatingOutperform$7.00N/A
i
Rating by Thomas Yip at (FBRC)
7/18/2016Noble FinancialReiterated RatingBuy$10.50N/A
i
7/17/2016(FBRC)Reiterated RatingOutperform$7.00N/A
i
Rating by Thomas Yip at (FBRC)
7/15/2016Roth CapitalReiterated RatingHold$3.50N/A
i
Rating by Joseph Pantginis at Roth Capital
6/4/2016(FBRC)Reiterated RatingBuy$7.00N/A
i
Rating by Thomas Yip at (FBRC)
5/20/2016(FBRC)Reiterated RatingOutperform$7.00N/A
i
Rating by Thomas Yip at (FBRC)
4/23/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Thomas Yip at (FBRC)
(Data available from 4/14/2016 forward)
Avid Bioservices logo
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Read More

Today's Range

Now: $19.70
$19.17
$19.76

50 Day Range

MA: $18.37
$16.01
$21.77

52 Week Range

Now: $19.70
$3.95
$22.13

Volume

5,715 shs

Average Volume

790,330 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Avid Bioservices?

The following Wall Street research analysts have issued stock ratings on Avid Bioservices in the last twelve months: HC Wainwright, KeyCorp, Royal Bank of Canada, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CDMO.

What is the current price target for Avid Bioservices?

3 Wall Street analysts have set twelve-month price targets for Avid Bioservices in the last year. Their average twelve-month price target is $17.33, suggesting a possible downside of 12.0%. KeyCorp has the highest price target set, predicting CDMO will reach $22.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $9.00 for Avid Bioservices in the next year.
View the latest price targets for CDMO.

What is the current consensus analyst rating for Avid Bioservices?

Avid Bioservices currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDMO will outperform the market and that investors should add to their positions of Avid Bioservices.
View the latest ratings for CDMO.

What other companies compete with Avid Bioservices?

How do I contact Avid Bioservices' investor relations team?

Avid Bioservices' physical mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company's listed phone number is 714-508-6100 and its investor relations email address is [email protected] The official website for Avid Bioservices is www.avidbio.com.